697 related articles for article (PubMed ID: 12119559)
21. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha.
van der Eijk AA; Niesters HG; Hansen BE; Heijtink RA; Janssen HL; Schalm SW; de Man RA
J Viral Hepat; 2006 Feb; 13(2):96-103. PubMed ID: 16436127
[TBL] [Abstract][Full Text] [Related]
22. Relationship between HBV genotypes and anti-viral therapeutic efficacy of interferon-alpha.
Ma JC; Wang LW; Li XJ; Liao YF; Hu XY; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):166-71. PubMed ID: 17374576
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers.
Kao JH; Chen PJ; Lai MY; Chen DS
J Med Virol; 2004 Mar; 72(3):363-9. PubMed ID: 14748059
[TBL] [Abstract][Full Text] [Related]
24. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
[TBL] [Abstract][Full Text] [Related]
25. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
[TBL] [Abstract][Full Text] [Related]
26. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.
Shindo M; Hamada K; Nishioji K; Muramatsu A; Oda Y; Okuno T
J Gastroenterol; 2004; 39(3):260-7. PubMed ID: 15065004
[TBL] [Abstract][Full Text] [Related]
27. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
Zhu M; Xu B; Yao GB
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
[TBL] [Abstract][Full Text] [Related]
28. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
29. Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis.
Yang YF; Zhao W; Xia HM; Zhong YD; Huang P; Wen J
Antiviral Res; 2010 Feb; 85(2):361-5. PubMed ID: 19900483
[TBL] [Abstract][Full Text] [Related]
30. Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2.
Stancek D; Fuchsberger N; Oltman M; Schmeisser H; Kontsek P; Jahnová E; Hajnická V
Acta Virol; 2001; 45(5-6):287-92. PubMed ID: 12083327
[TBL] [Abstract][Full Text] [Related]
31. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
Yao G; Cui Z; Wang B; Yao J; Zeng M
Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
[TBL] [Abstract][Full Text] [Related]
32. Chronic HBV infection. Immunomodulation with levamisole in viremic HBeAg positive or anti-HBe positive patients--a pilot study.
Krastev Z; Jelev D; Antonov K; Alagozian V; Kotzev I
Hepatogastroenterology; 1999; 46(30):3184-8. PubMed ID: 10626183
[TBL] [Abstract][Full Text] [Related]
33. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of viral replication in children with chronic hepatitis B with and without interferon treatment.
Lazăr C; Grigorescu-Sido P; Manasia R; Mireştean S; Skorka C; Neculoiu D; Molnar G; Cocean S
Rom J Gastroenterol; 2005 Sep; 14(3):219-24. PubMed ID: 16200230
[TBL] [Abstract][Full Text] [Related]
35. [The relationship between HBV genotypes and the efficacy of antiviral therapies in hepatitis B e antigen- positive patients].
Zou HB; Zhu LM; Zhao GM; Liang SR; Li J; Lu CZ; Li H
Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):425-7. PubMed ID: 17594806
[TBL] [Abstract][Full Text] [Related]
36. Relationship between viral load and genotypes of hepatitis B virus in children with chronic hepatitis B.
Oommen PT; Wirth S; Wintermeyer P; Gerner P
J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):342-7. PubMed ID: 16954957
[TBL] [Abstract][Full Text] [Related]
37. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
Karabay O; Tamer A; Tahtaci M; Vardi S; Celebi H
J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of different combination therapies for children with HBeAg positive chronic hepatitis B].
Zhong XH; Deng X; Chen XC; Zhou BP
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):62-3. PubMed ID: 17429539
[TBL] [Abstract][Full Text] [Related]
40. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
